In summary, we found that lower pharmacological selectivity of SGLT2 inhibitors with a more pronounced inhibitory effect on SGLT1 is associated with reduced risk of fatal and nonfatal stroke in high-risk type 2 diabetic patients, according to large-scale cardiovascular outcome trials. Here, SLC5A1 is linked to Stroke.